Pre-clinical study supports remdesivir as COVID-19 treatment
Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
List view / Grid view
Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
The bioreactor-based system incorporates liver cells to perform the detoxifying functions of the liver and was tested on pigs with acute liver failure.
The Brain Metastasis Cell Lines Panel compiles research from various international institutions on the numerous brain metastasis cell lines that have been developed, in hopes collaboration will expedite research and drug development.
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
Researchers have developed 'nanosponges' cloaked in lung cell membranes and macrophage membranes which they found could attract and neutralise COVID-19 in cell cultures.
4 June 2020 | By Biosensing Instrument
In this webinar, we will provide an overview of the technology with some application examples and also see a case study how AstraZeneca is exploring SPRM for studies on G-protein-coupled receptors (GPCR) in close collaboration with Biosensing Instrument.
Learn why researchers turned to biophysical methods to expose the molecular mechanisms of neurodegenerative diseases.
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
Parainfluenza 3 (PI3V) is a virus that causes respiratory diseases in calves, from the common cold to advanced pneumonia.
Learn practical tips from eight Principal Investigators about how to start your own lab.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.